background image

Paid Clinical Trials Sioux Falls

Discover 226 paid clinical trials in Sioux Falls, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: 120 recruiting locations
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting
Active & Responsive

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: 7 recruiting locations
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06544655

Phase1, Recruiting
Active & Responsive

Helix Research Network

for
Genetic Predisposition to Disease, Genetics Disease
Location: 10 recruiting locations
Sponsor: Helix, Inc

Sex: All

Age: 18+

Code: NCT06057181

Recruiting
Active & Responsive

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for
Prostate Cancer Metastatic
Location: 28 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0+

Code: NCT06136624

Phase3, Recruiting
Active & Responsive

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: 25 recruiting locations
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06982521

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

for
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma,
Location: 16 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05458297

Phase2, Recruiting
Active & Responsive

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for
Recurrent Endometrial Carcinoma,
Location: 219 recruiting locations
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05554328

Phase2, Recruiting
Active & Responsive

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for
Colorectal Neoplasms
Location: 63 recruiting locations
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT05253651

Phase3, Recruiting
Active & Responsive

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

for
Non-small Cell Lung Cancer (NSCLC)
Location: 18 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06305754

Phase3, Recruiting
Active & Responsive

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: 23 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase3, Recruiting